Levothyroxine Recall Targets Subpotent Tablets

Multiple lots of levothyroxine sodium tablets are being pulled from retail channels across the United States in a nationwide Class II recall after testing indicated the tablets may be subpotent, officials said. The issue was identified through routine stability testing, which suggested the affected tablets could contain less active ingredient than the label states.

The tablets were manufactured by Lupin Pharmaceuticals and distributed by Major Pharmaceuticals and Cardinal Health, according to the recall information. Officials said the action is aimed at preventing dispensing of the impacted lots while pharmacies and healthcare providers verify what inventory remains in stock.

United States Recall scope: seven strengths and distribution starting January 2025 Distribution of the affected products began in January The recall covers seven strengths of levothyroxine sodium tablets, spanning doses from 25 micrograms to 150 micrograms, officials said. Distribution of the affected products began in January 2025. The lots included in the action carry expiration dates running through January 2027, according to the recall notice. Pharmacies and healthcare providers are expected to check whether they have impacted inventory by matching lot numbers against official recall data and verifying stock on hand to avoid dispensing recalled product. Regulators cite “medium-risk” classification and patient sensitivity Regulators classified the event as a Class II recall, describing it as a medium-risk situation. Officials said reduced potency could lead to temporary or medically reversible health effects, while severe outcomes are considered remote. Because levothyroxine is used to manage thyroid hormone Because levothyroxine is used to manage thyroid hormone levels, officials noted that changes in potency may be significant for certain patients, especially those whose dosing is carefully calibrated. The notice states that treatment decisions should be individualized and guided by clinicians.

Guidance for patients and retail-level recall limits

Patients were advised not to stop taking levothyroxine Patients were advised not to stop taking levothyroxine without first consulting a healthcare professional. Officials cautioned that suddenly stopping therapy can pose greater clinical risk than continuing treatment while a replacement is arranged.

The recall is described as limited to the retail level. As a result, pharmacies are not required to contact individual patients directly, increasing the importance of inventory checks and clinician awareness in settings where dispensing records can be reviewed.

Officials also encouraged healthcare providers to review the official lot details and consider diagnostic blood testing for patients who report symptoms consistent with hypothyroidism. The notice points to symptom-driven evaluation as one way to identify potential impacts from lower-than-labeled potency.

Why stability testing and recall communication are central

Officials said the case demonstrates how post-manufacturing monitoring, including stability testing, can detect quality issues that may emerge over time after products have already been distributed. They also highlighted a communication challenge in retail-level recalls involving widely used chronic medications, particularly when patient notification is not mandatory.

For patients who may be affected, officials indicated that the safest next steps depend on clinical circumstances and should be determined with a clinician. For pharmacies and providers, the notice emphasizes verifying inventory against official lot data to reduce the risk of recalled tablets remaining in circulation.